An ASCO update panel has issued guidelines for adjuvant endocrine therapy in premenopausal women with estrogen receptor-positive breast cancer. Their guideline includes:

• Higher-risk patients should receive ovarian suppression in addition to adjuvant endocrine therapy, whereas lower-risk patients should not.

• Women with stage II or III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression with endocrine therapy.

• Some women with stage I or II breast cancers at higher risk of recurrence who might consider chemotherapy may also be offered ovarian suppression with endocrine therapy.

• Women with stage I breast cancers not warranting chemotherapy should not receive ovarian suppression, nor should women with node-negative cancers 1 cm or less.

• Ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor.

Citation: Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. [Published online ahead of print February 16, 2016]. Clin Oncol. doi:10.1200/JCO.2015.65.9573.